West Pharmaceutical Services, Inc. (NYSE:WST) VP Quintin J. Lai Sells 9,672 Shares

West Pharmaceutical Services, Inc. (NYSE:WST) VP Quintin J. Lai sold 9,672 shares of West Pharmaceutical Services stock in a transaction that occurred on Friday, September 10th. The shares were sold at an average price of $460.76, for a total transaction of $4,456,470.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NYSE WST opened at $452.06 on Wednesday. The firm has a market cap of $33.44 billion, a PE ratio of 66.09, a PEG ratio of 1.96 and a beta of 1.00. The firm has a fifty day moving average of $420.21 and a 200 day moving average of $353.74. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.39 and a current ratio of 3.13. West Pharmaceutical Services, Inc. has a one year low of $253.85 and a one year high of $475.35.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 29th. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.74 by $0.72. West Pharmaceutical Services had a net margin of 20.58% and a return on equity of 28.58%. The business had revenue of $723.60 million during the quarter, compared to analyst estimates of $665.55 million. On average, equities analysts predict that West Pharmaceutical Services, Inc. will post 8.22 EPS for the current fiscal year.

Separately, KeyCorp lifted their target price on shares of West Pharmaceutical Services from $350.00 to $475.00 and gave the company an “overweight” rating in a report on Friday, July 30th.

Several institutional investors have recently added to or reduced their stakes in WST. FMR LLC grew its holdings in shares of West Pharmaceutical Services by 41.3% during the first quarter. FMR LLC now owns 794 shares of the medical instruments supplier’s stock worth $88,000 after buying an additional 232 shares in the last quarter. IFP Advisors Inc boosted its position in shares of West Pharmaceutical Services by 34.4% during the 1st quarter. IFP Advisors Inc now owns 246 shares of the medical instruments supplier’s stock valued at $70,000 after acquiring an additional 63 shares during the last quarter. Signaturefd LLC boosted its position in shares of West Pharmaceutical Services by 15.3% during the 1st quarter. Signaturefd LLC now owns 340 shares of the medical instruments supplier’s stock valued at $96,000 after acquiring an additional 45 shares during the last quarter. Daiwa Securities Group Inc. boosted its position in shares of West Pharmaceutical Services by 4.6% during the 1st quarter. Daiwa Securities Group Inc. now owns 3,776 shares of the medical instruments supplier’s stock valued at $1,064,000 after acquiring an additional 165 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of West Pharmaceutical Services during the 1st quarter valued at about $49,000. 92.74% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers.

Featured Story: Purposes and Functions of the Federal Reserve

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.